tiprankstipranks
iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results
Company Announcements

iTeos Therapeutics Reports Positive Phase 2 Cancer Trial Results

Don't Miss our Black Friday Offers:

iTeos Therapeutics ( (ITOS) ) has provided an update.

iTeos Therapeutics has revealed promising interim results from the Phase 2 GALAXIES Lung-201 study, demonstrating significant improvements in treating advanced PD-L1 high non-small cell lung cancer with the combination of belrestotug and dostarlimab. This treatment showed a meaningful objective response rate, outperforming dostarlimab monotherapy, and has a safety profile consistent with existing checkpoint inhibitor combinations. The data supports the ongoing Phase 3 trial and will be further discussed in an upcoming conference call hosted by the company.

For an in-depth examination of ITOS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskiTeos Therapeutics Reports Q3 2024 Financial Results
TheFlyiTeos Therapeutics reports Q3 EPS ($1.05), consensus (89c)
TipRanks Italy Auto-Generated NewsdeskOfficina Stellare Secures €1.4 Million Satellite Contract
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App